Publications

Metzger D, Greenspun B, Siolas D, Jafari M.  2025.  ASO Author Reflections: Risk Stratification Using Genomic Data for Early-Stage Colon Cancer.. Ann Surg Oncol. 32(5):3851.

Karimi A, Bogdani C, O’Dwyer E, Siolas D.  2025.  Emerging Innovations in Theranostics for Pancreatic Neuroendocrine Tumors.. npj Precision Oncology.

Metzger DAryeh, Greenspun BC, Brouwer J, Li Y, Pigazzi A, Siolas D, Jafari MD.  2025.  Genomic Signatures of Recurrence After Resection of Early-Stage Node-Negative Colon Cancer.. Ann Surg Oncol. 32(5):3774-3780.

McIntyre CA, Grimont A, Park J, Meng Y, Sisso WJ, Seier K, Jang GHo, Walch H, Aveson VG, Falvo DJ et al..  2024.  Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer.. Cancer Cell. 42(9):1614-1629.e5.

Narayan VM, Siolas D, Meadows ES, Turzhitsky V, Sillah A, Imai K, McMurry AJ, Li H.  2023.  Evaluation of a Natural Language Processing Model to Identify and Characterize Patients in the United States With High-Risk Non-Muscle-Invasive Bladder Cancer.. JCO Clin Cancer Inform. 7:e2300096.

Kasi PMurtaza, Hidalgo M, Jafari MD, Yeo H, Lowenfeld L, Khan U, Nguyen ATH, Siolas D, Swed B, Hyun J et al..  2023.  Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer.. Oncogene. 42(44):3252-3259.

Wan S, Zhao E, Weissinger D, Krantz BA, Werba G, Freeman D, Khanna LG, Siolas D, Oberstein PE, Chattopadhyay PK et al..  2023.  Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies.. Front Immunol. 14:1067352.

Siolas D, Vucic E, Kurz E, Hajdu C, Bar-Sagi D.  2021.  Gain-of-function p53R172H mutation drives accumulation of neutrophils in pancreatic tumors, promoting resistance to immunotherapy.. Cell Rep. 36(8):109578.

Yin L, Criscito MC, Stokar E, Siolas D, Haimovic A, Sicco KLo, Brinster NK.  2021.  Papillary Dermal Elastolysis Secondary to Combination Nivolumab and Cabiralizumab Therapy: Histiocytes and Dermal Mucin as Clues to the Diagnosis.. Am J Dermatopathol. 43(10):746-749.

Siolas D, Morrissey C, Oberstein PEliezer.  2020.  The Achilles' Heel of Pancreatic Cancer: Targeting pancreatic cancer's unique immunologic characteristics and metabolic dependencies in clinical trials.. J Pancreatol. 3(3):121-131.

Cullis J, Siolas D, Avanzi A, Barui S, Maitra A, Bar-Sagi D.  2017.  Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer.. Cancer Immunol Res. 5(3):182-190.

Siolas D, Hannon GJ.  2013.  Patient-derived tumor xenografts: transforming clinical samples into mouse models.. Cancer Res. 73(17):5315-9.

Liu-Sullivan N, Zhang J, Bakleh A, Marchica J, Li J, Siolas D, Laquerre S, Degenhardt YY, Wooster R, Chang K et al..  2011.  Pooled shRNA screen for sensitizers to inhibition of the mitotic regulator polo-like kinase (PLK1).. Oncotarget. 2(12):1254-64.

Silva JM, Li MZ, Chang K, Ge W, Golding MC, Rickles RJ, Siolas D, Hu G, Paddison PJ, Schlabach MR et al..  2005.  Second-generation shRNA libraries covering the mouse and human genomes.. Nat Genet. 37(11):1281-8.

Siolas D, Lerner C, Burchard J, Ge W, Linsley PS, Paddison PJ, Hannon GJ, Cleary MA.  2005.  Synthetic shRNAs as potent RNAi triggers.. Nat Biotechnol. 23(2):227-31.